openPR Logo
Press release

Recurrent Glioblastoma Multiforme Gbm Treatment Market to Record an Exponential CAGR by 2022

Recurrent Glioblastoma Multiforme Gbm Treatment Market

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.

A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/10112

Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.

Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.

Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end user and geography.

Based on treatment, GBM market can be segmented as follows:

Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation therapy
Chemotherapy
Based on end user, GBM market can be segmented as follows:

Hospitals
Clinics
Ambulatory surgical centers
Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.

Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.

Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/10112

The report covers exhaustive analysis on:

Recurrent Glioblastoma Multiforme (GBM) Treatment Market Segments
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Dynamics
Historical Actual Market Size, 2013 - 2015
Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size & Forecast 2016 to 2022
Recurrent Glioblastoma Multiforme (GBM) Treatment Current Trends/Issues/Challenges
Competition & Companies involved
Recurrent Glioblastoma Multiforme (GBM) Treatment Drivers and Restraints
Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recurrent Glioblastoma Multiforme Gbm Treatment Market to Record an Exponential CAGR by 2022 here

News-ID: 731260 • Views: 280

More Releases from Persistence Market Research

Connected Homes Market to Reach a Valuation Higher than US$ 138 Bn by 2026
Connected Homes Market 2021-2026 New Study Reports " Connected Homes Market 2021 Global Opportunities, Challenges, Strategies and Forecasts 2026" has been Added on PersistenceMarketResearch. Report Details: This report provides in depth study of “Connected Homes Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Connected Homes Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling,
Iot Market 2021: Global Projection by Key Players – IBM Corporation, Microsoft …
Iot Market 2021-2026 New Study Reports " Iot Market 2021 Global Opportunities, Challenges, Strategies and Forecasts 2026" has been Added on PersistenceMarketResearch. Report Details: This report provides in depth study of “Iot Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Iot Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the
Mobile Advertising Market 2021 Expected to reach US$ 120 Billion with 18.8% CAGR …
Mobile Advertising Market 2021-2025 New Study Reports " Mobile Advertising Market 2021 Global Opportunities, Challenges, Strategies and Forecasts 2025" has been Added on PersistenceMarketResearch. Report Details: This report provides in depth study of “Mobile Advertising Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Mobile Advertising Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling,
Building Automation Systems Market 2021 Expected to reach 248 Bn US$ with 11.3% …
Building Automation Systems Market 2021-2031 New Study Reports " Building Automation Systems Market 2021 Global Opportunities, Challenges, Strategies and Forecasts 2031" has been Added on PersistenceMarketResearch. Report Details: This report provides in depth study of “Building Automation Systems Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Building Automation Systems Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an

All 5 Releases


More Releases for GBM

Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Multiforme Treatment (GBM) Market is exhibiting a positive CAGR of …
Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents. Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary: ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 20 …
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging